Latest Nootropics Stories
A new study published online in the Journal of Pediatrics suggests that neither attention deficit hyperactivity disorder (ADHD) nor medications used to treat it have a long-term impact on kids' growth. Previous studies have shown that medication may make kids with ADHD eat less and grow slower than their peers that do not have the condition. According to the Center for Disease Control and Prevention, about 10 percent of boys and 6 percent of girl shave been diagnosed with ADHD....
Further research is neededCancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic (http://www.mayoclinic.org/oncology-rst/) and the North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG) recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data...
FRAZER, Pa., June 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL® (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal. The analysis of the data showed that treatment with armodafinil did not lessen the severity of the negative symptoms of...
PHILADELPHIA, May 19 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, will present scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments Vyvanse® (lisdexamfetamine dimesylate) Capsules CII and INTUNIV(TM) (guanfacine) Extended Release Tablets at two national scientific meetings for psychiatrists May 20-26, 2010 in New Orleans, LA. "We believe that the Vyvanse and INTUNIV study findings will be an...
CHICAGO, May 11 /PRNewswire/ -- Adderall is a drug widely reported to increase alertness, concentration and overall cognitive performance, while decreasing fatigue - but it is also a drug widely abused across college campuses. During final exams time and throughout the year, students are consuming this highly addictive drug in order to study, as well as in many cases to lose weight due to the loss of appetite realized when Adderall is taken. Prescribed on a regular basis to treat ADHD and...
WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease. The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition...
SAN FRANCISCO, May 3 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss first quarter 2010 financial results and provide a general business update on May 10, 2010, at 4:30 p.m. Eastern Time. A press release for the first quarter ended March 31, 2010 will be released after markets close on May 10, 2010. Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally....
MORRISTOWN, N.J., April 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the U.S. Court of Appeals for the Federal Circuit Court has affirmed a March 31, 2009 District Court decision that the asserted claims of ALZA's United States Patent No. 6,919,373 "the '373 Patent" are invalid. The original suit by ALZA Corporation and McNeil-PPC, Inc. alleged that Watson's generic versions of Concerta® (methylphenidate hydrochloride extended-release...
TITUSVILLE, N.J., April 26 /PRNewswire/ -- The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision by the U.S. District Court of Delaware that the patent for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation. In December 2007, McNeil Pediatrics, which markets CONCERTA, and ALZA Corporation, the owner of the CONCERTA...
FRAZER, Pa., AESCH, Switzerland and MAISONS-ALFORT, France, April 9 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is...
